Exact Sciences Corporation (EXAS) Stock Analysis
Healthcare · Diagnostics & Research
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and... Read more
TrendMatrix rates Exact Sciences Corporation (EXAS) as Sell with moderate confidence. The stock trades at $104.95 with -1.9% upside to the $102.88 price target. Overall score: 5.5/10 across 10 analysis dimensions. Reward/risk ratio: -0.4:1.
Passes 3/4 gates (positive momentum, clean insider activity, no SEC red flags). Fails on favorable risk/reward ratio. Suitability: aggressive.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates Exact Sciences Corporation (EXAS) as Sell with moderate confidence. Score 5.5/10.
Take-profit target: $102.88 (-1.9% upside). Reward/risk ratio: -0.4:1. Stop-loss: $99.86.
Analyst target reached - limited upside remaining; Near 52-week high (0.1% away); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0).
Exact Sciences Corporation trades at a P/E of N/A (forward 55.2). TrendMatrix value score: 5.5/10. Verdict: Sell.
29 analysts cover EXAS with a consensus score of 3.3/5. Average price target: $106.
What does Exact Sciences Corporation do?Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and...
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.